1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Global Market Study on Treatment for Syndromes of Dementia and Movement Disorders: Asia to Witness Highest Growth by 2020

Dementia refers to a group of mental disorders that causes progressive decline in the intellectual functioning of a person. The precise cause of dementia is unknown and it depends upon the type of mental disorder a person is suffering from. Dementia is one of the major causes of disability among the elderly population. In addition, with the rise in aging population, the proportion of patients with neurodegenerative diseases is also surging. The treatment of movement disorder and dementia depends upon the cause of the disease. It is treated symptomatically with the help of biological therapy and medications such as small molecules. In addition, awareness about mental diseases has risen in various parts of the world owing to growing investments and initiatives undertaken by private and public health institutions. Increasing prevalence of neurodegenerative disorders, rising awareness about mental diseases, and growing R&D investments in drug discovery and developments are the key driving factors of the treatment for syndromes of dementia and movement disorders market.

On the other hand, strict regulatory requirement and long approval time for drugs, and lack of comprehensive therapeutic management of dementia and movement disorders are major concerns for the market. In addition, most of the drugs fail in Phase III due to lack of sufficient knowledge about the mechanisms of the brain and the unknown causes of the disease. Rising number of collaborations and partnerships is the major trend in the market leading to rise in discovery and development of dementia and movement disorder drugs.

North America dominates the global market for treatment for syndromes of dementia and movement disorders due to large number of aging population and increasing incidence of neurodegenerative diseases. Asia is expected to show high growth rates in the next five years in the global treatment for syndromes of dementia and movement disorders market. Some of the key driving forces for treatment for syndromes of dementia and movement disorders market in emerging countries are increasing geriatric population, large pool of patients and rising awareness of mental disorders. In addition, various initiative programs are organized to improve the status of awareness about dementia and movement disorders.

This report provides in-depth analysis and estimation of the treatment for syndromes of dementia and movement disorders market for the period 2014 to 2020, considering 2013 as the base year for calculation. In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report. The treatment for syndromes of dementia and movement disorders market is categorized on the basis of the drugs used to treat progressive dementia, drugs used to treat progressive dementia with neurological abnormalities, drugs used to treat movement disorder syndromes, and geography. Based on drugs used to treat progressive dementia, progressive dementia with neurological abnormalities and movement disorder syndromes the market comprises of disease based therapeutics and drug category. On the basis of geography, the report identifies and analyses the market size and predictions for North America, Europe, Asia, and Rest of the World (RoW).

Some of the major players in the treatment for syndromes of dementia and movement disorders market are F. Hoffmann-La Roche, Ltd., Novartis AG, Merck & Co., Inc., Sanofi S.A., Valeant Pharmaceutical International, Inc., AstraZeneca GmbH and Pfizer, Inc. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Table Of Contents

Global Market Study on Treatment for Syndromes of Dementia and Movement Disorders: Asia to Witness Highest Growth by 2020
Chapter 1 Preface

1.1 Report Description

1.2 Research Methodology

1.3 Assumptions

Chapter 2 Market Synopsis

Chapter 3 Porter's Five Forces Analysis

3.1 Bargaining Power of Suppliers

3.2 Bargaining Power of Buyers

3.3 Threat of New Entrants

3.4 Threat of Substitutes

3.5 Intensity of Rivalry

Chapter 4 Industry Overview

4.1 Market Definition

4.2 Market Drivers

4.2.1 Increasing prevalence of neurodegenerative diseases

4.2.2 Rising awareness about mental diseases

4.2.3 Increasing RandD investments in drug discovery and developments

4.3 Impact Analysis of Market Drivers

4.4 Market Restraints

4.4.1 Strict regulatory requirements and long approval time for drugs

4.4.2 Lack of comprehensive therapeutic management of dementia and movement disorders

4.5 Impact Analysis of Market Restraints

4.6 Market Trend

4.6.1 Rising number of collaborations and partnerships would lead to rise in research and discovery of dementia and movement disorder drugs

Chapter 5 Global Market Size and Forecast

Chapter 6 Market Size and Forecast by Drugs Used to Treat Progressive Dementia

6.1 Diseases Based Therapeutics Under Progressive Dementia

6.2 Drugs for Progressive Dementia

Chapter 7 Market Size and Forecast by Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities

7.1 Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities

7.2 Drugs for Progressive Dementia

Chapter 8 Market Size and Forecast by Drugs Used to Treat Movement Disorder Syndrome

8.1 Diseases Based Therapeutics Under Movement Disorder Syndrome

8.2 Drugs for Movement Disorder Syndrome

Chapter 9 Market Size and Forecast by Geography

9.1 North America

9.2 Europe

9.3 Asia

Chapter 10 Competitive Scenario

10.1 Competitive Benchmarking

Chapter 11 Company Profiles

11.1 F. Hoffmann-La Roche, Ltd.

11.1.1 Company overview

11.1.2 Products and services

11.1.3 Financial performance

11.1.4 Key developments

11.2 Baxter

11.2.1 Company overview

11.2.2 Products and services

11.2.3 Financial performance

11.2.4 Key development

11.3 Novartis AG

11.3.1 Company overview

11.3.2 Products and services

11.3.3 Financial performance

11.3.4 Key developments

11.4 Merck and Co., Inc.

11.4.1 Company overview

11.4.2 Products and services

11.4.3 Financial performance

11.4.4 Key developments

11.5 Sanofi

11.5.1 Company overview

11.5.2 Products and services

11.5.3 Financial performance

11.5.4 Key developments

11.6 Pfizer, Inc.

11.6.1 Company overview

11.6.2 Products and services

11.6.3 Financial performance

11.6.4 Key developments

11.7 Valeant Pharmaceuticals International, Inc.

11.7.1 Company overviews

11.7.2 Products and services

11.7.3 Financial performance

11.7.4 Key developments

11.8 AstraZeneca GmbH

11.8.1 Company overview

11.8.2 Products and services

11.8.3 Financial performance

11.8.4 Key developments

11.9 Abbott Laboratories, Inc.

11.9.1 Company overview

11.9.2 Products and services

11.9.3 Financial performance

11.9.4 Key developments

11.10 Bristol-Myers Squibb Company

11.10.1 Company overview

11.10.2 Products and services

11.10.3 Financial performance

11.10.4 Key developments

List of Tables

TABLE 1 Market snapshot: Treatment for syndromes of dementia and movement disorders market, 2014 and 2020

TABLE 2 Drivers for global treatment for syndrome of dementia and movement disorders market: Impact analysis

TABLE 3 Estimated average timelines for clinical trial approval in various countries

TABLE 4 Restraints for global treatment for syndromes of dementia and movement disorders market: Impact analysis

TABLE 5 Major collaborations and partnerships by dementia and movement disorder treatment companies (2011 - 2013)

TABLE 6 Global treatments for syndromes of dementia and movement disorders market size, by region, 2010 - 2013 (USD million)

TABLE 7 Global treatments for syndromes of dementia and movement disorders market size, by region, 2014 - 2020 (USD million)

TABLE 8 Global treatments for syndromes of dementia and movement disorders market size, by segment, 2010 - 2013 (USD million)

TABLE 9 Global treatments for syndromes of dementia and movement disorders market size, by segment, 2014 - 2020 (USD million)

TABLE 10 Global progressive dementia therapeutic market size, by disease, 2010 - 2013 (USD million)

TABLE 11 Global progressive dementia therapeutic market size, by disease, 2014 - 2020 (USD million)

TABLE 12 Global progressive dementia market size, by drug category, 2010 - 2013 (USD million)

TABLE 13 Global progressive dementia market size, by drug category, 2014 - 2020 (USD million)

TABLE 14 Global progressive dementia with other neurological abnormalities therapeutics market size, by disease, 2010 - 2013 (USD million)

TABLE 15 Global progressive dementia with other neurological abnormalities therapeutic market size, by disease, 2014 - 2020 (USD million)

TABLE 16 Global progressive dementia with other neurological abnormalities market size, by drug category, 2010 - 2013 (USD million)

TABLE 17 Global progressive dementia with other neurological abnormalities market size, by drug category, 2014 - 2020 (USD million)

TABLE 18 Global movement disorder syndrome therapeutics market size, by disease, 2010 - 2013 (USD million)

TABLE 19 Global movement disorder syndrome therapeutics market size, by disease, 2014 - 2020 (USD million)

TABLE 20 Global movement disorders market size, by drug category, 2010 - 2013 (USD million)

TABLE 21 Global movement disorder market size, by drug category, 2014 - 2020 (USD million)

TABLE 22 The North American treatment for syndromes of dementia and movement disorders market size, by country, 2010 - 2013 (USD million)

TABLE 23 The North American treatment for syndromes of dementia and movement disorders market size, by country, 2014 - 2020 (USD million)

TABLE 24 The North American treatments for syndromes of dementia and movement disorders market size, by segment, 2010 - 2013 (USD million)

TABLE 25 The North American treatments for syndromes of dementia and movement disorders market size, by segment, 2014 - 2020 (USD million)

TABLE 26 The European treatment for syndromes of dementia and movement disorders market size, by country, 2010 - 2013 (USD million)

TABLE 27 The European treatment for syndromes of dementia and movement disorders market size, by country, 2014 - 2020 (USD million)

TABLE 28 The European treatments for syndromes of dementia and movement disorders market size, by segment, 2010 - 2013 (USD million)

TABLE 29 The European treatments for syndromes of dementia and movement disorders market size, by segment, 2014 - 2020 (USD million)

TABLE 30 The Asian treatment for syndromes of dementia and movement disorders market size, by country, 2010 - 2013 (USD million)

TABLE 31 The Asian treatment for syndromes of dementia and movement disorders market size, by country, 2014 - 2020 (USD million)

TABLE 32 The Asian treatments for syndromes of dementia and movement disorders market size, by segment, 2010 - 2013 (USD million)

TABLE 33 The Asian treatments for syndromes of dementia and movement disorders market size, by segment, 2014 - 2020 (USD million)

TABLE 34 F. Hoffmann-La Roche, Ltd.'s product categories

TABLE 35 Baxter's product categories

TABLE 36 Novartis AG's product categories

TABLE 37 Merck and Co., Inc.'s product categories

TABLE 38 Sanofi's product categories

TABLE 39 Pfizer, Inc.'s product categories

TABLE 40 Valeant Pharmaceuticals International, Inc.'s product categories

TABLE 41 AstraZeneca GmbH's product categories

TABLE 42 Abbott Laboratories, Inc.'s product categories

TABLE 43 Bristol-Myers Squibb Company's product categories

List of Figures

FIG. 1 Treatment for syndromes of dementia and movement disorders market: Porter's five forces analysis

FIG. 2 Types of dementia and movement disorders 18

FIG. 3 Global treatments for syndromes of dementia and movement disorders market share, by region, by value, 2013

FIG. 4 Global treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013

FIG. 5 Global progressive dementia therapeutic market share, by disease, by value, 2013

FIG. 6 Global progressive dementia market share, by drug category, by value, 2013

FIG. 7 Global progressive dementia with other neurological abnormalities therapeutics market share, by disease, by value, 2013

FIG. 8 Global progressive dementia with other neurological abnormalities market share, by drug category, by value, 2013

FIG. 9 Global movement disorder syndrome therapeutics market share, by disease, by value, 2013

FIG. 10 Global movement disorder syndrome market share, by drug category, by value, 2013

FIG. 11 The North American treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013

FIG. 12 The North American treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013

FIG. 13 The European treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013

FIG. 14 The European treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013

FIG. 15 The Asian treatment for syndromes of dementia and movement disorders market share, by country, by value, 2013

FIG. 16 The Asian treatments for syndromes of dementia and movement disorders market share, by segment, by value, 2013

FIG. 17 Competitive landscape of treatment providers for syndromes of dementia and movement disorders, 2013

FIG. 18 F. Hoffmann-La Roche, Ltd.'s sales and net income, 2011 - 2013 (USD million)

FIG. 19 Baxter's net sales and net income, 2011 - 2013 (USD million)

FIG. 20 Novartis AG's net sales and net income, 2011 - 2013 (USD million)

FIG. 21 Merck and Co., Inc.'s sales and net income, 2011 - 2013 (USD million)

FIG. 22 Sanofi net sales and net income, 2011 - 2013 (USD million)

FIG. 23 Pfizer, Inc.'s revenue and net income, 2011 - 2013 (USD million)

FIG. 24 Valeant Pharmaceuticals International, Inc.'s revenues and net income/loss, 2011 - 2013 (USD million)

FIG. 25 AstraZeneca GmbH's revenues and profit, 2011 - 2013 (USD million)

FIG. 26 Abbott Laboratories' net sales and net earnings, 2011 - 2013 (USD million)

FIG. 27 Bristol-Myers Squibb's revenue and net earnings, 2011 - 2013 (USD million)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Alzheimer’s disease ...

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

"Global Multi Infarct Dementia Market Research Report 2016" by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.